Raymond James & Associates Dyne Therapeutics, Inc. Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
A detailed history of Raymond James & Associates transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 49,027 shares of DYN stock, worth $688,829. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,027
Previous 100,750
51.34%
Holding current value
$688,829
Previous $3.56 Million
50.46%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding DYN
# of Institutions
211Shares Held
122MCall Options Held
36.5KPut Options Held
74.3K-
Ra Capital Management, L.P. Boston, MA9.71MShares$136 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$133 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$128 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$107 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$104 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $727M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...